← Back to Clinical Trials
Recruiting NCT03686709

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Trial Parameters

Condition Hepatocellular Carcinoma
Sponsor University of Tennessee
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2018-06-19
Completion 2019-06-18
Interventions
Post therapy PET/CT Imaging

Brief Summary

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Eligibility Criteria

Inclusion Criteria: * All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study * Must be able to schedule and tolerate additional PET/CT imaging following therapy * Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure. Exclusion Criteria: * Patients that are not candidates for Y90 radioembolization therapy * Patients that cannot tolerate additional imaging procedures following therapy * Patients that cannot tolerate the additional blood draws required for this study * Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study

Related Trials